Trends in Use of Telemedicine for Stimulant Initiation Among Children and Adults
- PMID: 38239181
- PMCID: PMC11216869
- DOI: 10.1176/appi.ps.20230421
Trends in Use of Telemedicine for Stimulant Initiation Among Children and Adults
Abstract
Objective: The authors sought to examine trends in stimulant initiation and follow-up care for attention-deficit hyperactivity disorder (ADHD) via telemedicine.
Methods: This retrospective longitudinal study used national, deidentified commercial health insurance outpatient claims among children (ages 2-17 years; N=535,629) and adults (ages 18-64 years; N=2,116,160) from January 2019 through April 2022. Regression analyses were used to examine risk for stimulant initiation, whether initiation occurred via telemedicine or in-person care, and receipt of a follow-up visit.
Results: The mean monthly adjusted number of stimulant initiations per 100,000 enrollees was similar for children before and during the COVID-19 pandemic (prepandemic, 57 initiations; during pandemic, 56 initiations) but increased for adults (prepandemic, 27 initiations; during pandemic, 33 initiations). Initiations via telemedicine peaked at 53%-57% in April 2020 and dropped to about 14% among children and 28% among adults in April 2022. Telemedicine initiations were significantly more common among psychiatrists than among other prescribers (OR=3.70, 95% CI=3.38-4.06 [children]; OR=3.02, 95% CI=2.87-3.17 [adults]) and less common for rural residents (OR=0.57, 95% CI=0.40-0.82 [children]; OR=0.75, 95% CI=0.61-0.92 [adults]). Follow-up care was significantly more common among individuals whose care was initiated via telemedicine than among those receiving in-person care (OR=1.09, 95% CI=1.00-1.19 [children]; OR=1.61, 95% CI=1.53-1.69 [adults]).
Conclusions: Many stimulant treatments were initiated via telemedicine. Proposed rules to prohibit controlled substance prescribing without an in-person evaluation would require significant changes in current practice, potentially limiting access to stimulant medications for ADHD.
Keywords: Amphetamine; Attention deficit disorders; Child psychiatry; Stimulants; Telecommunications.
Conflict of interest statement
Dr. Mehrotra has received fees related to telemedicine from Black Opal Ventures, Commonwealth of Massachusetts, NORC, Pew Charitable Trust, and Sanofi. The other authors report no financial relationships with commercial interests.
Figures


Similar articles
-
Recent Trends in Medication Treatment for Attention-Deficit Hyperactivity Disorder.Psychiatr Serv. 2025 Sep 1;76(9):782-787. doi: 10.1176/appi.ps.20240574. Epub 2025 May 28. Psychiatr Serv. 2025. PMID: 40432373
-
Trends In Telehealth Initiation Of Prescription Stimulants For Child And Adult Enrollees In Medicaid And CHIP During COVID-19.Health Aff (Millwood). 2025 Aug;44(8):996-1004. doi: 10.1377/hlthaff.2024.01659. Health Aff (Millwood). 2025. PMID: 40758925
-
Telehealth Prescribing of Stimulants for ADHD and Associated Risk for Later Stimulant and Substance Use Disorders.Am J Psychiatry. 2025 Aug 1;182(8):779-788. doi: 10.1176/appi.ajp.20240346. Epub 2025 Jun 11. Am J Psychiatry. 2025. PMID: 40495525
-
Stimulant and non-stimulant drug therapy for people with attention deficit hyperactivity disorder and epilepsy.Cochrane Database Syst Rev. 2022 Jul 13;7(7):CD013136. doi: 10.1002/14651858.CD013136.pub2. Cochrane Database Syst Rev. 2022. PMID: 35844168 Free PMC article.
-
Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of adverse events in non-randomised studies.Cochrane Database Syst Rev. 2018 May 9;5(5):CD012069. doi: 10.1002/14651858.CD012069.pub2. Cochrane Database Syst Rev. 2018. PMID: 29744873 Free PMC article.
Cited by
-
Recent Trends in Medication Treatment for Attention-Deficit Hyperactivity Disorder.Psychiatr Serv. 2025 Sep 1;76(9):782-787. doi: 10.1176/appi.ps.20240574. Epub 2025 May 28. Psychiatr Serv. 2025. PMID: 40432373
-
Perceptions of stimulant and buprenorphine diversion and strategies to address it.Health Aff Sch. 2024 Jun 3;2(6):qxae074. doi: 10.1093/haschl/qxae074. eCollection 2024 Jun. Health Aff Sch. 2024. PMID: 38934014 Free PMC article.
-
Treating Attention-Deficit/Hyperactivity Disorder Matters.JAMA. 2024 Mar 12;331(10):831-833. doi: 10.1001/jama.2024.1755. JAMA. 2024. PMID: 38470393 Free PMC article. No abstract available.
References
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous